Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Peginterferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PLATINUM
- Sponsors Biogen
- 17 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 15 May 2017 Planned End Date changed from 1 Jul 2017 to 30 Dec 2017.
- 15 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Dec 2017.